You are here: Industry Insights > Market News > AstraZeneca signs manufacturing pact with Chinese firm, BioKangtai for COVID-19 vaccine

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!

Note: You can unsubscribe from the alerts at any time.

Advertising

New Products

water filter

WATER FILTER FOR WATER PURIFIER

DUST BAG

Small dust filter

HUMIDIFIER FILTER

Oil fume adsorption filter

AstraZeneca signs manufacturing pact with Chinese firm, BioKangtai for COVID-19 vaccine

expresspharmaAugust 07, 2020

Tag: AstraZeneca , Biokangtai , COVID-19 vaccine

Favorites

AstraZeneca has entered into an agreement with a Chinese vaccine manufacturer BioKangtai to produce 100 million doses of its COVID-19 vaccine candidate AZD1222, when completed, in China by the end of 2020. AstraZeneca is developing this vaccine in a partnership with Oxford University.

The British company announced about this deal through a post on Chinese social platform WeChat.

As per the deal, AstraZeneca will deliver the first 100 million doses this year and 200 million doses by the end of 2021. It also stipulates a commitment for the two firms to explore distributing a vaccine in other markets.

Previous:Xi'an Sanjiang Bio-engineering Co. Ltd.- Exhibitor Webinar

Next:Unichem gets US FDA approval for Tolterodine Tartrate tablets

Thrombolytic Science Announces FDA’s IND Clearance of Mutant Prourokinase for the Treatment of Thrombotic Diseases

PharmaSourcesOctober 15, 2024

Thrombolytic Science, LLC (TSI), announced today that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for mutant prourokinase, a recombinant fibrinolytic pro-enzyme.

Eleva Appoints Dr. Elisabeth Lackner to its Supervisory Board Adding Broad Biopharmaceutical Industry Expertise to the Organization

PharmaSourcesOctober 15, 2024

BrainDos™ Formulated Dual GIP/GLP-1 Receptor Agonist Tirzepatide Outperforms Tirzepatide Solution (Mounjaro®) in Preclinical Study

PharmaSourcesOctober 15, 2024

AstraZeneca signs manufacturing pact with Chinese firm, BioKangtai for COVID-19 vaccine | Pharmasources.com

BD and ten23 health® Partner to Advance Efficiency and Quality in Aseptic Manufacturing with RFID-Enabled Prefillable Syringes

PharmaSourcesOctober 15, 2024

BD and ten23 health today announced a collaboration to develop a new way to track prefillable syringes (PFS) using RFID technology.

AstraZeneca signs manufacturing pact with Chinese firm, BioKangtai for COVID-19 vaccine

Related News

Thrombolytic Science Announces FDA’s IND Clearance of Mutant Prourokinase for the Treatment of Thrombotic Diseases

Eleva Appoints Dr. Elisabeth Lackner to its Supervisory Board Adding Broad Biopharmaceutical Industry Expertise to the Organization

BrainDos™ Formulated Dual GIP/GLP-1 Receptor Agonist Tirzepatide Outperforms Tirzepatide Solution (Mounjaro®) in Preclinical Study

BD and ten23 health® Partner to Advance Efficiency and Quality in Aseptic Manufacturing with RFID-Enabled Prefillable Syringes

You may like
More>>

AstraZeneca signs manufacturing pact with Chinese firm, BioKangtai for COVID-19 vaccine

Related News

Thrombolytic Science Announces FDA’s IND Clearance of Mutant Prourokinase for the Treatment of Thrombotic Diseases

Eleva Appoints Dr. Elisabeth Lackner to its Supervisory Board Adding Broad Biopharmaceutical Industry Expertise to the Organization

BrainDos™ Formulated Dual GIP/GLP-1 Receptor Agonist Tirzepatide Outperforms Tirzepatide Solution (Mounjaro®) in Preclinical Study

BD and ten23 health® Partner to Advance Efficiency and Quality in Aseptic Manufacturing with RFID-Enabled Prefillable Syringes

You may likeMore>>

You may like
More>>